Safety and effectiveness of phenobarbital vs. benzodiazepines for severe alcohol withdrawal in alcohol-associated liver disease in the ICU

This is the first large study to evaluate phenobarbital vs. benzodiazepines for severe alcohol withdrawal specifically in patients with alcohol-associated liver disease, a population often excluded from prior research. This study provides important evidence showing that phenobarbital yields comparable respiratory and mortality outcomes to benzodiazepines in critically ill patients with alcohol-associated liver disease. These findings are important for hepatologists, intensivists, and hospital clinicians who face therapeutic uncertainty and safety concerns regarding benzodiazepine use in this group. Establishing phenobarbital as a viable alternative could help inform future clinical guidelines and support safer, evidence-based management of withdrawal in patients with advanced liver disease.